Fig. 7: Synthesis of C@MSN-P-A8 and its molecular mechanism in osteoporosis treatment.
From: Bone-targeted celastrol nanocarrier suppresses osteoclastogenesis in postmenopausal osteoporosis
A Synthesis process of Bone-Targeted Nano Sustained Release Materials C@MSN-P-A8. B Molecular mechanism schematic of C@MSN-P-A8 for preventing and treating postmenopausal osteoporosis by inhibiting osteoclast formation and bone resorption through the suppression of the NF-κB and MAPK signaling pathways.
